profit from every $100 of sales.
$0$100
ICON Public
$199.70-2.41% today
+22.2% in 1 year
1-year low $80.081-year high $215.48
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $65.23 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What ICON Public sold, what it kept, and what it did with the cash.
Sales went from $7.74 billion in 2022 to $8.25 billion in 2025, with $229 million of profit last year.
SalesProfit
ICON Public handed back 87% of the cash it generated last year.
Buybacks $750M
Free cash flow 2025$862M
Bought back its own shares$750M
Paid as dividends–
Cash vs. debt$647M vs. $3.6B
ICON Public vs. similar companies
ICON Public grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| ICON Public | 65.2× · Very expensive | ||
 Illumina | 37.9× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads ICON Public's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 7,741 | 8,055 | 8,189 | 8,251 | |
| 2,214 | 2,349 | 2,371 | 2,176 | |
| 866 | 994 | 1,154 | 1,012 | |
| 1,347 | 1,470 | 1,498 | 824 | |
| 505 | 554 | 739 | 229 | |
| 6.13 | 7.40 | 9.53 | 2.90 | |
| 28.6% | 29.2% | 29.0% | 26.4% | |
| 11.2% | 12.3% | 14.1% | 12.3% | |
| 6.5% | 6.9% | 9.0% | 2.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 17,185 | 16,865 | 16,635 | 16,270 |
| Cash | 289 | 378 | 539 | 647 |
| Total debt | 4,829 | 3,938 | 3,603 | 3,556 |
| Total liabilities | 8,687 | 7,653 | 7,193 | 7,076 |
| 8,498 | 9,211 | 9,441 | 9,193 | |
| 83 | 83 | 83 | 79 | |
| 4.6% | 5.3% | 6.1% | 2.7% | |
| 5.9% | 6.0% | 7.8% | 2.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 563 | 1,161 | 1,287 | 1,036 | |
| 142 | 141 | 168 | 174 | |
| 421 | 1,020 | 1,119 | 862 | |
| Dividends paid | – | – | – | – |
| 100 | 0 | 500 | 750 | |
| 71 | 56 | 46 | 102 |
Valuation
- 65.2×
- 16.8×
- –
- 1.3×
- 1.8×
- 17.4×
- 21.7×
- 5.8%
- 1.5%
- 0.0%
Profitability
- 26.4%
- 12.3%
- 2.8%
- 15.9%
- 6.0%
- 3.5%
- 5.2%
- 3.0%
- 6.9%
- –
Growth
- +2.1%
- −22.1%
- −22.9%
- –
- +4.0%
Financial health
- 2.2×
- 0.39
- 21.9%
- 4.8×
- 1.10
- 1.10
- 0.50
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 47%of 958
Top 42%of 888
Bottom 16%of 600
Bottom 22%of 889
Top 18%of 987
What analysts expect
- Average price target
- $152.13
- Range
- $100.00 – $222.00
- 6 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Oct 22, 2025 | 3.31 | 3.28 | +0.9% |
| Jul 23, 2025 | 3.26 | 3.19 | +2.2% |
| Apr 30, 2025 | 3.19 | 3.11 | +2.6% |
| Feb 19, 2025 | 3.43 | 3.41 | +0.6% |
| Oct 23, 2024 | 3.35 | 3.85 | −13.0% |
| Jul 24, 2024 | 3.75 | 3.68 | +1.9% |
| Apr 24, 2024 | 3.47 | 3.41 | +1.8% |
| Feb 21, 2024 | 3.46 | 3.44 | +0.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
49No pass
Philip Fisher
11No pass
Peter Lynch
20No pass
Joel Greenblatt
3No pass
Charlie Munger
11No pass
Terry Smith
14No pass
Questions about ICON Public
Is ICON Public a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ICON Public AI analysis
What does ICON Public do?
ICON Public Limited Company operates as a global clinical research organization (CRO), delivering outsourced development and commercialization services across Ireland, continental Europe, the United States, and various other international regions. It is in Medical - Diagnostics & Research, based in Dublin, Ireland, with 40,100 employees.
Does ICON Public pay a dividend?
No. ICON Public does not pay a dividend at the moment; in 2025 it returned $750 million to shareholders by buying back its own shares.
Is ICON Public stock halal?
Yes. ICON Public passes our halal screen: its business is permitted and its debt is 24% of its market value, under the 30% limit. How we check
How has ICON Public stock done over the past year?
Up 22.2% over the past twelve months, to $199.70. It traded between $80.08 and $215.48 and is 7.3% below its high.
Who are ICON Public's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with ICON Public's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.